ANZCTR search results

Previous studies have shown specialized dietary fibre supplements can prevent type 1 diabetes in mice by altering the gut bacteria, reducing inflammation around the body and preventing the autoimmune destruction of the insulin-producing cells in the pancreas. While this fibre supplement has been used to treat other health conditions in humans, it has yet to be determined whether humans with type 1 diabetes will experience the same protection as mice. This pilot research trial therefore aims to determine whether a large clinical trial of this fibre supplement that releases high concentrations of the natural products, acetate and butyrate, is a) feasible, b) safe and c) well-tolerated in adults with established type 1 diabetes, and to (d) determine whether this supplement affects any markers of diabetes, such as changes in the gut microbiota and inflammatory markers, which would indicate the supplement would have a similar effect on type 1 diabetes protection in humans as in mice. To achieve these aims, we will conduct a pilot study in 25 adults with pre-existing type 1 diabetes consuming the dietary fibre supplement twice daily for 6 weeks, with a follow-up at 12 weeks. The supplement is an ordourless, tasteless powder that dissolves easily in cold or hot foods. Eligible participants will attend the study centre on 4 separate occasions (baseline, 3, 6 and 12 weeks) and will receive dietary counselling and an individualised plan for the times of day they take the supplement and the specific foods in their usual diet they incorporate it into. Participants will be monitored closely for changes in their blood, urine and stool pathology, their blood glucose control, insulin requirements, and any side effects or feedback on the supplement. Blood and stool samples will also be taken to at each visit to assess the preliminary efficacy of the dietary supplement and ensure the laboratory experiments are feasible for a future large clinical trial.

This research project is being conducted to investigate the safety, tolerability, and pharmacokinetics of single ascending dose and multiple ascending dose of oral EHP-101 when administered in healthy adult subjects.

This study will involve the creation of a Knowledge Translation Hub and a network of specialist therapy centres in Australia. The translational hub will inform and guide stakeholders in knowledge translation, upskill therapists and establish a community of practice. The specialist therapy centres will deliver SENSe to people with stroke, and provide training to upskill therapists. The study will monitor a range of outcomes including touch sensation, functional use of the hand, and return to personally-important activities for survivors of stroke, therapist confidence to deliver SENSe, and costs to implement the service. The project has been funded by the NHMRC as a partnership grant to implement evidence into practice.

The purpose of the present project is to investigate whether individuals in early bereavement can reduce cardiovascular risk by taking therapy (beta-blocker and aspirin)

AIMS: This research project aims to collect information about the processes and outcomes of antibiotic allergy testing in a standardised way in order to improve future quality of care and outcomes for people with antibiotic allergies. The focus of this project will be on individuals with penicillin allergy labels. PARTICIPANTS: Patients who present to a hospital specialist service for assessment of penicillin allergy will be asked if they would like to participate. METHODS: Collection of information that will be routinely collected at the patient's routine penicillin allergy assessment visit and a follow up telephone call or email 8 weeks after the visit. An optional blood sample may be collected on the day to store for future research related to drug allergy. EXPECTED OUTCOMES: Improve access to antibiotic allergy delabelling services, improve the way in which appropriate advice after delabelling is provided to patients, and develop education resources for teaching and implementation of best practice into other nonhospital settings. This will provide safer and more cost effective care for all.

The aim of this project is to assess the impact of providing longer term tube feeding in patients with oesophageal cancer who are undergoing oesophagectomy. Who is it for? You may be eligible to join this study if you are aged 18 years or over and a have oesophageal cancer undergoing oesophagectomy at the John Hunter Hospital, NSW. Study details Study participants will be allocated by chance to either the intervention of the standard care control group. Participants in the intervention group will receive a tube feed supplying 20kCal/kg and 1g/kg protein per day (approx. 60-70% of requirements) for 12 weeks post operatively compared to a control group who will be tube fed at the same level (20kCal/kg and 1g/kg Protein) for the usual period of six weeks. On discharge all patients will be provided with standardised education regarding appropriate high energy and high protein foods and be guided through the process of reintroducing foods from puree to soft texture. It is hoped that this study will help us understand whether extending the period of tube feeding after oesophagectomy leads to better nutritional status outcomes compared to current tube feeding length.

The primary aim is to evaluate the effectiveness of a 6month programme of trauma-sensitive yoga (TSY), with mindfulness elements in a sample of ex-serving Defence members with a clinical diagnosis of combat-related PTSD. A secondary aim is to evaluate the effectiveness of the intervention for partners of participating ex-serving members. The study will be conducted at the Jamie Larcombe Centre by clinical staff trained in TSY. A sample of no less than 34 ex-serving Defence members will be recruited and provided with a 90minute session of TSY each week for 6 months. Data will be collected before the intervention and repeated at one, three and six months and after an additional three month follow-up. Analysis will determine change in PTSD and associated mental health symptoms in veterans. Outcomes will contribute to the emerging evidence base for yoga as an adjuvant treatment for PTSD. A convenience sample of partners will be recruited with qualitative analysis undertaken to understand their views on the effects of the programme on themselves, their partners and their relationships. The term 'partner' refers to the domestic/domiciliary partners of ex-serving Defence members. They have been included on the basis that they are in a position to offer support to the ex-serving Defence members that are the primary subjects of the study, and may also stand to benefit from participation.

The aim of this study is to determine whether an antiseptic mouthwash (twice a day over a 14-days period) can be used as an alternative treatment for oropharyngeal gonorrhoea without using antibiotics. If mouthwash can be used as an alternative treatment, then it would provide a possible treatment if gonorrhoea were to become multi-resistant, something that is clearly concerning the WHO and US CDC.

Aneurysmal subarachnoid haemorrhage (aSAH) is a rare but devastating form of stroke caused by a ruptured brain aneurysm that kills at least 30% of sufferers within 1 month. Up to 50% of people with aSAH will experience delays greater than 24 hours between onset of aSAH and receiving treatment. This study aims to quantify the time delays in treatment of aSAH for patients across Tasmania and South-East Victoria.

Many women receive chemotherapy to decrease the chance of breast cancer recurrence after surgery. These drugs include chemotherapy which is collectively termed taxane-based chemotherapy. Though this is effective in decreasing recurrence, it may cause adverse effects which include peripheral neuropathy, or damage to the nerves, particularly in the hands and feet. This nerve damage can be disabling, causing difficulty in work-related tasking such as typing on a keyboard, difficulty holding objects or fastening buttons. If severe, it can impair the ability to drive or cause falls. We hope to test a better way of detecting peripheral neuropathy than our current grading system, so that early symptoms can be identified and treatment changed to prevent this. Who is it for? You may be eligible for this study if you have a diagnosis of breast cancer and your oncologist plans to use weekly paclitaxel in your treatment plan. Study details If you participate, you will complete a form with details of pre-existing health problems and symptoms of neuropathy You will complete the neuropathy symptom tool (EORTC QLQ CIPN20) on cycle 1 day 1 of chemotherapy, then at 3, 6, 9, 12 weeks into your treatment There will be no additional visits. Your oncologist will not see the results of these questionnaires so if you have symptoms you should also discuss these with your oncologist in your clinic appointment. It is hoped this research will demonstrate that EORTC QLQ CIPN20 is more sensitive than standard practice, and could be used to identify neuropathy earlier that would allow modifications to treatment to be made before more severe symptoms develop.